DIN 02497875 — ENTYVIO 108 MG
ENTYVIO is a solution of Vedolizumab marketed by TAKEDA CANADA INC. The full Vedolizumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02497875
- Brand name
- ENTYVIO
- Active ingredient
- Vedolizumab
- Strength
- 108 MG
- Dosage form
- SOLUTION
- Route
- SUBCUTANEOUS
- Manufacturer
- TAKEDA CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Gut-selective anti-inflammatory biologic (alpha4beta7 integrin antagonist monoclonal antibody)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Vedolizumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02497867 | ENTYVIO | 108 MG | SOLUTION | TAKEDA CANADA INC | MARKETED |
| 02436841 | ENTYVIO | 300 MG | POWDER FOR SOLUTION | TAKEDA CANADA INC | MARKETED |